US20060093579A1 - Human recombinant beta-interferon with improved solubility - Google Patents

Human recombinant beta-interferon with improved solubility Download PDF

Info

Publication number
US20060093579A1
US20060093579A1 US11/280,997 US28099705A US2006093579A1 US 20060093579 A1 US20060093579 A1 US 20060093579A1 US 28099705 A US28099705 A US 28099705A US 2006093579 A1 US2006093579 A1 US 2006093579A1
Authority
US
United States
Prior art keywords
leu
ser
glu
asn
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/280,997
Other versions
US7575894B2 (en
Inventor
Christian Schneider-Fresenius
Bernd Otto
Gero Waschutza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/280,997 priority Critical patent/US7575894B2/en
Publication of US20060093579A1 publication Critical patent/US20060093579A1/en
Application granted granted Critical
Publication of US7575894B2 publication Critical patent/US7575894B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Definitions

  • the invention pertains to variants of human recombinant beta-interferon with improved solubility.
  • Beta-interferon is a regulatory protein which leads to activation of genes by binding receptors. As a result, antiviral, antiproliferative and further biological activities are mediated in the cell.
  • inteferons as is also the case with the interleukins, belong to the class of cytokines and are subdivided into different classes:
  • Type I interferon alpha, beta, omega, tau
  • Type II gamma
  • Human beta-interferon is a protein with a molecular weight of 22 kDa and 166 amino acid residues. It is formed primarily in fibroblasts during attack by a virus and possesses antiviral, antiproliferative and further biological activities.
  • the amino acid sequence of human beta-interferon was first published by Taniguchi et al. (1980), Gene Ed. 10, pages 11 through 15, and is illustrated in FIG. 1 .
  • Beta-interferon which is produced from bacterial cells or mammalian cells by genetic engineering, is being used successfully in the treatment of multiple sclerosis, a previously incurable disease in a large group of patients.
  • the very high hydrophobicity of the protein which causes very poor solubility of recombinant human beta-interferon, proves to be problematical for the production and processing of recombinant human beta-interferon.
  • the problem for the present invention is to make available variants of recombinant human beta-interferon whose solubility is improved in polar media, such as e.g. aqueous liquids.
  • an objective of this invention is to indicate processes for manufacturing and possibilities for using variants of recombinant human beta-interferon with higher solubility in polar media such as aqueous liquids.
  • At least one of the following ten hydrophobic amino acids in known human beta-interferon is exchanged for a hydrophilic amino acid: Leu 5, Phe 8, Phe 15, Leu 47, Phe 50, Leu 106, Phe 111, Leu 116, Leu 120 or Phe 156.
  • a hydrophilic amino acid Leu 5, Phe 8, Phe 15, Leu 47, Phe 50, Leu 106, Phe 111, Leu 116, Leu 120 or Phe 156.
  • the designated amino acids are essentially located on the surface of human beta-interferon and they take up a relatively large proportion of the surface there.
  • the exchange of these amino acids therefore leads to more than a proportionately large improvement in the hydrophilic character of the surface of recombinant human beta-interferon and it therefore increases the solubility of this protein in polar media, such as e.g. aqueous liquids.
  • polar media such as e.g. aqueous liquids.
  • the recombinant human beta-interferon in accordance with the invention is considerably simpler to handle in production as well as during its processing to give an active substance.
  • the production of the variants of recombinant human beta-interferon in accordance with the invention takes place in a generally known, conventional way with the help of microorganisms, e.g. in an Escherichia coli culture which has been provided with the gene for one of the proteins in accordance with the invention.
  • the production of these microorganisms, which have been changed by means of genetic engineering, also takes place in a generally known way with the help of classical genetic engineering mutagenesis procedures for the exchange of the corresponding amino acids for hydrophilic amino acids and their synthesis will therefore be dispensed with at this juncture.
  • the proteins in accordance with the invention find use for the manufacture of medicinal drugs, e.g. for combatting multiple sclerosis, as well as fine chemicals for in vitro experiments or for measurements of interferon levels.
  • the improved hydrophilicity of these proteins thereby simplifies their manufacture, transportation, storage and application in the form of a medicinal drug or fine chemical.
  • serine is especially suitable for exchange since especially slight steric changes in the protein are associated with it.
  • the amino acid sequence of native recombinant human beta-interferon in which the above-mentioned ten amino acids are electively exchanged for serine, is illustrated in FIG. 2 .
  • These exchangeable amino acids are represented by Xaa. If these amino acids are exchanged, then the hydrophilicity of the surface of recombinant human beta-interferon is very much improved whereas only slight impairment arises in terms of the functionality and the efficacy of human recombinant beta-interferon.
  • FIG. 3 An especially advantageous further development is illustrated in FIG. 3 in which all of the above-mentioned ten amino acids have been exchanged here for serine so that an especially marked increase in the hydrophilicity of the surface of recombinant human beta-interferon results.
  • FIG. 1 shows native human recombinant beta-interferon
  • FIG. 2 shows the variants of recombinant human beta-interferon in accordance with the invention
  • FIG. 3 shows a recombinant human beta-interferon [variant] in accordance with the invention.
  • FIG. 4 shows primers for the mutagenesis for the manufacture of beta-interferon in accordance with the invention.
  • FIG. 1 describes native human recombinant beta-interferon in the form in which it can already be manufactured currently with the help of known molecular biological and bio-technical possibilities.
  • FIG. 2 The sequence of native human recombinant beta-interferon is illustrated in FIG. 2 in which Xaa designates those amino acids which can be exchanged for an amino acid with at least one hydroxy group (advantageously serine, tyrosine and/or threonine) and hence result in a recombinant human beta-interferon [variant] in accordance with the invention which possesses increased surface hydrophilicity.
  • FIG. 3 shows an example of a human recombinant beta-interferon [variant] in which the following amino acids have been exchanged for serine:
  • the multiple variant with amino acid exchanges at positions 47, 50, 106, 111, 116 and 120 also shows activity which corresponds to the beta-interferon starting protein, with a Cys17Ser exchange, which was used in this example.
  • Mutagenesis takes place by means of a PCR (polymerase chain reaction).
  • the mutations are introduced via synthetic oligonucleotides.
  • Plasmid DNA with the beta-IFN gene [translator: beta-INF gene?] serves as the template.
  • the entire plasmid was replicated with the PCR method which was used here.
  • the selection of the PCR fragments takes place by means of restriction digestion of the entire PCR mixture with the enzyme DpnI. This enzyme recognizes only methylated interfaces. Since fragments, which are produced in vitro by means of PCR, are unmethylated, only the template DNA is degraded by DpnI. After DpnI digestion, in the event of success, a fragment with the length of the linearized template remains behind and this carries the mutations.
  • PCR fragments that are produced, are cloned and sequenced.
  • PCR mixture 100 ml: template DNA 10 mg primers 100 pmol each nucleotide mix 200 mM per dNTP MgSO 4 2-6 mM DNA polymerase 2.5 units PCR protocol Duration Temperature step 1. 4 min 95 C. step 2. + enzyme step 3. 45 sec 95 C. step 4. 1 min 55 C. step 5. 10 min 68 C. goto [sic] 3. (11x) step 6. 10 min 68 C. step 7. 4 C.
  • the PCR was carried out in a Thermocycler PTC-200 (MJ Research company).
  • Two primers are necessary for each PCR, namely a “forward” primer and a “reverse” primer.
  • the two primers follow one another directly but, in each case, they bind to different strands with the opposite orientation.
  • FIG. 4 illustrates primers which were used for the mutagenesis in order that the amino acid(s), that are designated on the left, be exchanged for serine in the gene product, i.e. the beta-interferon in accordance with the invention.
  • the last two primers alone contain “reverse” primer mutations.
  • a PCR with these primers additionally introduces mutations without the previously inserted mutations 5 ⁇ 8 or 106/111 being relinquished. If the wild type is taken as a template, then four mutations can be introduced at the same time via the “reverse” primers (5-17 or, as the case may be, 106-120).

Abstract

The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Description

  • The invention pertains to variants of human recombinant beta-interferon with improved solubility.
  • Beta-interferon is a regulatory protein which leads to activation of genes by binding receptors. As a result, antiviral, antiproliferative and further biological activities are mediated in the cell.
  • The inteferons, as is also the case with the interleukins, belong to the class of cytokines and are subdivided into different classes:
  • Type I interferon (alpha, beta, omega, tau) and Type II (gamma)
  • Human beta-interferon is a protein with a molecular weight of 22 kDa and 166 amino acid residues. It is formed primarily in fibroblasts during attack by a virus and possesses antiviral, antiproliferative and further biological activities. The amino acid sequence of human beta-interferon was first published by Taniguchi et al. (1980), Gene Ed. 10, pages 11 through 15, and is illustrated in FIG. 1.
  • Beta-interferon, which is produced from bacterial cells or mammalian cells by genetic engineering, is being used successfully in the treatment of multiple sclerosis, a previously incurable disease in a large group of patients. However, the very high hydrophobicity of the protein, which causes very poor solubility of recombinant human beta-interferon, proves to be problematical for the production and processing of recombinant human beta-interferon.
  • The problem for the present invention is to make available variants of recombinant human beta-interferon whose solubility is improved in polar media, such as e.g. aqueous liquids. In addition, an objective of this invention is to indicate processes for manufacturing and possibilities for using variants of recombinant human beta-interferon with higher solubility in polar media such as aqueous liquids.
  • This problem is solved by the recombinant human beta-interferon in accordance with claim 1, its use in accordance with claim 5 and its manufacture in accordance with claim 6 or 7.
  • In accordance with claim 1, at least one of the following ten hydrophobic amino acids in known human beta-interferon is exchanged for a hydrophilic amino acid: Leu 5, Phe 8, Phe 15, Leu 47, Phe 50, Leu 106, Phe 111, Leu 116, Leu 120 or Phe 156. Thus the invention pertains to individual mutations as well as to all the possible combinations of these individual amino acid exchanges.
  • The designated amino acids are essentially located on the surface of human beta-interferon and they take up a relatively large proportion of the surface there. The exchange of these amino acids therefore leads to more than a proportionately large improvement in the hydrophilic character of the surface of recombinant human beta-interferon and it therefore increases the solubility of this protein in polar media, such as e.g. aqueous liquids. As a result of its increased hydrophilicity, the recombinant human beta-interferon in accordance with the invention is considerably simpler to handle in production as well as during its processing to give an active substance.
  • The production of the variants of recombinant human beta-interferon in accordance with the invention takes place in a generally known, conventional way with the help of microorganisms, e.g. in an Escherichia coli culture which has been provided with the gene for one of the proteins in accordance with the invention. The production of these microorganisms, which have been changed by means of genetic engineering, also takes place in a generally known way with the help of classical genetic engineering mutagenesis procedures for the exchange of the corresponding amino acids for hydrophilic amino acids and their synthesis will therefore be dispensed with at this juncture.
  • The proteins in accordance with the invention find use for the manufacture of medicinal drugs, e.g. for combatting multiple sclerosis, as well as fine chemicals for in vitro experiments or for measurements of interferon levels. The improved hydrophilicity of these proteins thereby simplifies their manufacture, transportation, storage and application in the form of a medicinal drug or fine chemical.
  • Advantageous further developments of the proteins in accordance with the invention are given in the dependent claims.
  • Exchange for the amino acids serine, tyrosine and threonine is especially advantageous and, with one hydroxy group each, these are especially hydrophilic.
  • As a result of its small size, serine is especially suitable for exchange since especially slight steric changes in the protein are associated with it.
  • The amino acid sequence of native recombinant human beta-interferon, in which the above-mentioned ten amino acids are electively exchanged for serine, is illustrated in FIG. 2. These exchangeable amino acids are represented by Xaa. If these amino acids are exchanged, then the hydrophilicity of the surface of recombinant human beta-interferon is very much improved whereas only slight impairment arises in terms of the functionality and the efficacy of human recombinant beta-interferon.
  • An especially advantageous further development is illustrated in FIG. 3 in which all of the above-mentioned ten amino acids have been exchanged here for serine so that an especially marked increase in the hydrophilicity of the surface of recombinant human beta-interferon results.
  • An example of a variant of human recombinant beta-interferon in accordance with the invention is given in the following sections:
  • FIG. 1 shows native human recombinant beta-interferon;
  • FIG. 2 shows the variants of recombinant human beta-interferon in accordance with the invention;
  • FIG. 3 shows a recombinant human beta-interferon [variant] in accordance with the invention; and
  • FIG. 4 shows primers for the mutagenesis for the manufacture of beta-interferon in accordance with the invention.
  • As already described above, FIG. 1 describes native human recombinant beta-interferon in the form in which it can already be manufactured currently with the help of known molecular biological and bio-technical possibilities.
  • The sequence of native human recombinant beta-interferon is illustrated in FIG. 2 in which Xaa designates those amino acids which can be exchanged for an amino acid with at least one hydroxy group (advantageously serine, tyrosine and/or threonine) and hence result in a recombinant human beta-interferon [variant] in accordance with the invention which possesses increased surface hydrophilicity.
  • By way of example, all ten individual variants of beta-interferon have been manufactured in which Leu (5), Phe (8), Phe (15), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116), Leu (120) or Phe (156) were exchanged for serine, whereby, in particular, the variants with exchange of the amino acids Leu (5), Phe (8), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116) and Leu (120) relative to native beta-interferon, and also these variants of the Cys-17-Ser variant of human beta-interferon, excel by virtue of comparable biological activity.
  • FIG. 3 shows an example of a human recombinant beta-interferon [variant] in which the following amino acids have been exchanged for serine:
  • Leu (5), Phe (8), Phe (15), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116), Leu (120) and Phe (156). In the case of this variant of recombinant human beta-interferon, especially high hydrophilicity of the surface of the protein results and, hence, especially good solubility in aqueous solutions.
  • For example, the multiple variant with amino acid exchanges at positions 47, 50, 106, 111, 116 and 120 also shows activity which corresponds to the beta-interferon starting protein, with a Cys17Ser exchange, which was used in this example.
  • The manufacture of organisms with a gene, which has been changed in accordance with the invention, for human recombinant beta-interferon takes place by means of classical mutagenesis procedures.
  • Mutagenesis takes place by means of a PCR (polymerase chain reaction). The mutations are introduced via synthetic oligonucleotides. Plasmid DNA with the beta-IFN gene [translator: beta-INF gene?] serves as the template. The entire plasmid was replicated with the PCR method which was used here. The selection of the PCR fragments takes place by means of restriction digestion of the entire PCR mixture with the enzyme DpnI. This enzyme recognizes only methylated interfaces. Since fragments, which are produced in vitro by means of PCR, are unmethylated, only the template DNA is degraded by DpnI. After DpnI digestion, in the event of success, a fragment with the length of the linearized template remains behind and this carries the mutations. The PCR fragments, that are produced, are cloned and sequenced.
    PCR mixture (100 ml): template DNA 10 mg
    primers
    100 pmol each
    nucleotide mix 200 mM per dNTP
    MgSO4 2-6 mM
    DNA polymerase 2.5 units
    PCR protocol Duration Temperature
    step
    1. 4 min 95 C.
    step
    2. + enzyme
    step
    3. 45 sec 95 C.
    step
    4.  1 min 55 C.
    step
    5. 10 min 68 C.
    goto [sic] 3. (11x)
    step 6. 10 min 68 C.
    step 7.  4 C.
  • The PCR was carried out in a Thermocycler PTC-200 (MJ Research company).
  • Two primers are necessary for each PCR, namely a “forward” primer and a “reverse” primer. The two primers follow one another directly but, in each case, they bind to different strands with the opposite orientation.
  • FIG. 4 illustrates primers which were used for the mutagenesis in order that the amino acid(s), that are designated on the left, be exchanged for serine in the gene product, i.e. the beta-interferon in accordance with the invention.
  • The last two primers alone contain “reverse” primer mutations. A PCR with these primers additionally introduces mutations without the previously inserted mutations ⅝ or 106/111 being relinquished. If the wild type is taken as a template, then four mutations can be introduced at the same time via the “reverse” primers (5-17 or, as the case may be, 106-120).

Claims (13)

1-4. (canceled)
5. Use of human recombinant beta-interferon wherein at least one of the amino acids Leu (5), Phe (8), Phe (15), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116), Leu (120), Phe (156) has been exchanged for amino acids with at least one hydroxy group for the manufacture of a medicinal drug, as a fine chemical for in vitro experiments, or for measurements of interferon levels.
6. A manufacturing process for a human recombinant beta-interferon, with use being made of a microorganism, which contains the gene for recombinant human beta-interferon, wherein the genetic code for at least one of the amino acids Leu (5), Phe (8), Phe (15), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116), Leu (120) or Phe (156) is exchanged in the gene for the recombinant human beta-interferon of the organism, for a genetic code for amino acids with at least one hydroxy group.
7. A manufacturing process for a human recombinant beta-interferon, with use being made of a microorganism, wherein the gene for human recombinant beta-interferon is inserted into the genetic material of the microorganism, whereby the genetic code for at least one of the amino acids Leu (5), Phe (8), Phe (15), Leu (47), Phe (50), Leu (106), Phe (111), Leu (116), Leu (120), Phe (156) of the inserted gene has been exchanged for a genetic code for amino acids with at least one hydroxy group.
8. The invention of claim 5 wherein the amino acids with at least one hydroxy group consist of at least one of serine, tyrosine and threonine.
9. The process of claim 6 wherein the amino acids with at least one hydroxy group consist of at least one of serine, tyrosine and threonine.
10. The manufacturing process of claim 7 wherein the amino acids with at least one hydroxy group consist of at least one of serine, tyrosine and threonine.
11. The invention of claim 5 wherein the human beta-interferon contains the amino acid of SEQ ID NO: 2, wherein the SEQ ID NO: 2 contains the following amino acid sequence:
Met Ser Tyr Asn Xaa Leu Gly Xaa Leu Gln Arg Ser 1               5                   10 Ser Asn Xaa Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                  20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Xaa Gln             40                  45 Gln Xaa Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Xaa Glu Lys             100                 105 Glu Asp Xaa Thr Arg Gly Lys Xaa Met Ser Ser Xaa     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                 130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Xaa Arg Asn Phe Tyr Xaa 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
whereby at least one or more of the amino acids Xaa(5), Xaa(8), Xaa (15), Xaa(47), Xaa(50), Xaa(106), Xaa(111), Xaa(116), Xaa(120), Xaa(156) is serine, tyrosine or threonine and the following applies to the other amino acids
Xaa(5) is Leu, Xaa(5) is Phe,
Xaa(15) is Phe, Xaa(47) is Leu,
Xaa(50) is Phe, Xaa(106) is Leu,
Xaa(111) is Phe, Xaa(116) is Leu,
Xaa(120) is Leu, Xaa(156) is Phe.
12. The invention of claim 8 wherein the human beta-interferon contains the amino acid of SEQ ID NO: 2, wherein the SEQ ID NO: 2 contains the following amino acid sequence:
Met Ser Tyr Asn Ser Leu Gly Ser Leu Gln Arg Ser 1               5                   10 Ser Asn Ser Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                  20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Ser Gln             40                  45 Gln Ser Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Ser Glu Lys             100                 105 Glu Asp Ser Thr Arg Gly Lys Ser Met Ser Ser Ser     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                 130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Ser 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
whereby at least one or more of the amino acids Xaa(5), Xaa(8), Xaa (15), Xaa(47), Xaa(50), Xaa(106), Xaa(111), Xaa(116), Xaa(120), Xaa(156) is serine, tyrosine or threonine and the following applies to the other amino acids
Xaa(5) is Leu, Xaa(5) is Phe,
Xaa(15) is Phe, Xaa(47) is Leu,
Xaa(50) is Phe, Xaa(106) is Leu,
Xaa(111) is Phe, Xaa(116) is Leu,
Xaa(120) is Leu, Xaa(156) is Phe.
13. Beta-interferon in accordance with claim 5 which contains the amino acid of SEQ ID NO: 3, wherein the SEQ ID NO: 3 contains the following amino acid sequence:
Met Ser Tyr Asn Ser Leu Gly Ser Leu Gln Arg Ser 1               5                   10 Ser Asn Ser Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                  20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Ser Gln             40                  45 Gln Ser Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Ser Glu Lys             100                 105 Glu Asp Ser Thr Arg Gly Lys Ser Met Ser Ser Ser     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Ser 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
14. Beta-interferon in accordance with claim 8 which contains the amino acid of SEQ ID NO: 3, wherein the SEQ ID NO: 3 contains the following amino acid sequence:
Met Ser Tyr Asn Ser Leu Gly Ser Leu Gln Arg Ser 1               5                   10 Ser Asn Ser Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                   20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Ser Gln             40                  45 Gln Ser Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Ser Glu Lys             100                 105 Glu Asp Ser Thr Arg Gly Lys Ser Met Ser Ser Ser     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                 130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Ser 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
15. Beta-interferon in accordance with claim 11 which contains the amino acid of SEQ ID NO: 3, wherein the SEQ ID NO: 3 contains the following amino acid sequence:
Met Ser Tyr Asn Ser Leu Gly Ser Leu Gln Arg Ser 32 1               5                   10 Ser Asn Ser Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                  20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Ser Gln             40                  45 Gln Ser Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Ser Glu Lys             100                 105 Glu Asp Ser Thr Arg Gly Lys Ser Met Ser Ser Ser     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                 130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Ser 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
16. Beta-interferon in accordance with claim 12 which contains the amino acid of SEQ ID NO: 3, wherein the SEQ ID NO: 3 contains the following amino acid sequence:
Met Ser Tyr Asn Ser Leu Gly Ser Leu Gln Arg Ser 1               5                   10 Ser Asn Ser Gln Cys Gln Lys Leu Leu Trp Gln Leu         15                  20 Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Met 25                  30                  35 Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Ser Gln             40                  45 Gln Ser Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr     50                  55                  60 Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln                 65                  70 Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val         75                  80 Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn 85                  90                  95 His Leu Lys Thr Val Leu Glu Glu Lys Ser Glu Lys             100                 105 Glu Asp Ser Thr Arg Gly Lys Ser Met Ser Ser Ser     110                 115                 120 His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr                 125                 130 Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr         135                 140 Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Ser 145                 150                 155 Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn             160                 165
US11/280,997 1997-04-23 2005-11-17 Human recombinant beta-interferon with improved solubility Expired - Fee Related US7575894B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/280,997 US7575894B2 (en) 1997-04-23 2005-11-17 Human recombinant beta-interferon with improved solubility

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19717864A DE19717864C2 (en) 1997-04-23 1997-04-23 Human recombinant interferon beta, process for its preparation and its use
DE19717864.2 1997-04-23
US09/403,532 US6572853B1 (en) 1997-04-23 1998-04-16 Recombinant human beta interferon with enhanced solubility
PCT/EP1998/002238 WO1998048018A1 (en) 1997-04-23 1998-04-16 Recombinant human beta interferon with enhanced solubility
US10/448,667 US7052687B2 (en) 1997-04-23 2003-05-30 Human recombinant beta-interferon with improved solubility
US11/280,997 US7575894B2 (en) 1997-04-23 2005-11-17 Human recombinant beta-interferon with improved solubility

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/448,667 Division US7052687B2 (en) 1997-04-23 2003-05-30 Human recombinant beta-interferon with improved solubility

Publications (2)

Publication Number Publication Date
US20060093579A1 true US20060093579A1 (en) 2006-05-04
US7575894B2 US7575894B2 (en) 2009-08-18

Family

ID=7827959

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/403,532 Expired - Lifetime US6572853B1 (en) 1997-04-23 1998-04-16 Recombinant human beta interferon with enhanced solubility
US10/448,667 Expired - Lifetime US7052687B2 (en) 1997-04-23 2003-05-30 Human recombinant beta-interferon with improved solubility
US11/280,997 Expired - Fee Related US7575894B2 (en) 1997-04-23 2005-11-17 Human recombinant beta-interferon with improved solubility

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/403,532 Expired - Lifetime US6572853B1 (en) 1997-04-23 1998-04-16 Recombinant human beta interferon with enhanced solubility
US10/448,667 Expired - Lifetime US7052687B2 (en) 1997-04-23 2003-05-30 Human recombinant beta-interferon with improved solubility

Country Status (10)

Country Link
US (3) US6572853B1 (en)
EP (1) EP0975761B1 (en)
JP (1) JP4189035B2 (en)
AT (1) ATE257859T1 (en)
CA (1) CA2287521C (en)
DE (2) DE19717864C2 (en)
DK (1) DK0975761T3 (en)
ES (1) ES2214709T3 (en)
PT (1) PT975761E (en)
WO (1) WO1998048018A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19717864C2 (en) * 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon beta, process for its preparation and its use
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
DE60232434D1 (en) 2001-02-27 2009-07-09 Maxygen Aps NEW INTERFERON-BETA-LIKE MOLECULES
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
ES2343518T3 (en) 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT.
US20040137581A1 (en) * 2002-10-01 2004-07-15 Xencor Interferon variants with improved properties
EP1636256A2 (en) * 2003-06-10 2006-03-22 Xencor, Inc. Interferon variants with improved properties
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
KR100781666B1 (en) 2004-11-02 2007-12-03 신영기 Human Interferon-beta Mutein
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
DE102008051574A1 (en) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for extracting a protein with interferon-beta-activity, comprises culturing cells with the ability to synthesize the protein in a culture medium containing a block copolymer of ethylene oxide and propylene oxide
EP2431051A1 (en) * 2010-09-15 2012-03-21 Vakzine Projekt Management GmbH Type-1 interferons for the treatment of multiple sclerosis
CN104080803B (en) 2011-10-01 2020-08-04 株式会社糖锁工学研究所 Sugar chain-added polypeptide and pharmaceutical composition containing the same
MY171183A (en) 2013-03-29 2019-09-30 Glytech Inc Polypeptide glycosylated with sialylated sugar chain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6572853B1 (en) * 1997-04-23 2003-06-03 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Recombinant human beta interferon with enhanced solubility

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6572853B1 (en) * 1997-04-23 2003-06-03 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Recombinant human beta interferon with enhanced solubility
US7052687B2 (en) * 1997-04-23 2006-05-30 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human recombinant beta-interferon with improved solubility

Also Published As

Publication number Publication date
DE59810596D1 (en) 2004-02-19
WO1998048018A1 (en) 1998-10-29
CA2287521C (en) 2009-08-11
CA2287521A1 (en) 1998-10-29
DE19717864A1 (en) 1998-10-29
EP0975761B1 (en) 2004-01-14
DE19717864C2 (en) 2001-05-17
ES2214709T3 (en) 2004-09-16
JP2001523957A (en) 2001-11-27
US20040022763A1 (en) 2004-02-05
JP4189035B2 (en) 2008-12-03
ATE257859T1 (en) 2004-01-15
US6572853B1 (en) 2003-06-03
PT975761E (en) 2004-05-31
US7052687B2 (en) 2006-05-30
US7575894B2 (en) 2009-08-18
EP0975761A1 (en) 2000-02-02
DK0975761T3 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
US20060093579A1 (en) Human recombinant beta-interferon with improved solubility
Dang et al. Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.
Clary et al. The mitochondrial DNA molecule of Drosophila yakuba: nucleotide sequence, gene organization, and genetic code
EP2351775A1 (en) Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof
JPH04154799A (en) Protein, dna and its use
DD202045A5 (en) METHOD FOR CLONING A DEOXYNUCLEOTIDE SEQUENCE
US20220213459A1 (en) Variant cas12 proteins with improved dna cleavage selectivity and methods of use
US6511823B1 (en) Heparin binding neurotrophic factor gene sequence
DE69926627T2 (en) INSULINARY GROWTH FACTOR BINDING PROTEIN -3 VARIANT
Scharf et al. The Mouse Region Syntenic for Human Spinal Muscular Atrophy Lies within theLgn1Critical Interval and Contains Multiple Copies ofNaipExon 5
CA2435712A1 (en) Universal carrier for targeting molecules to gb3 receptor expressing cells
HOMMA et al. The DNA sequence encoding pldA gene, the structural gene for detergent-resistant phospholipase A of E. coli
JPWO2021050571A5 (en)
KR920012440A (en) Human interleukin-5 receptor
Barrell et al. Nucleotide sequence of a glycine transfer RNA coded by bacteriophage T4
CN1065875C (en) Fibrillating cell growth factor-2 analogue and its production method and use
WO1992013948A1 (en) Cloning of a new member of the fibroblast growth factor (fgf) receptor family
DE4233782A1 (en) Human embryonal kinase 2-receptor protein - useful in tumour diagnosis and therapy
GALLAGHER et al. Primary structure of rat ribosomal protein L36a
Deisseroth et al. Study of markers of human erythroid differentiation in hybrid cells
CN106167524B (en) Secapin peptides from eastern bees
JPS60126088A (en) Novel dna and its use
DE3428370A1 (en) Interferon, genetic sequences which code therefor, and organisms producing these
AU2016218635B2 (en) Molecular design of recombinant protein drug
Anfinsen Human interferon

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210818